Intervention Review

You have free access to this content

Bisphosphonates for osteoporosis in people with cystic fibrosis

  1. Louise S Conwell1,2,*,
  2. Anne B Chang3

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 14 MAR 2014

Assessed as up-to-date: 13 MAR 2014

DOI: 10.1002/14651858.CD002010.pub4


How to Cite

Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD002010. DOI: 10.1002/14651858.CD002010.pub4.

Author Information

  1. 1

    Lady Cilento Children's Hospital, Endocrinology and Diabetes, Brisbane, Queensland, Australia

  2. 2

    University of Queensland, School of Medicine and Queensland Children's Medical Research Institute, Herston, Queensland, Australia

  3. 3

    Menzies School of Health Research, Charles Darwin University, Child Health Division, Darwin, Northern Territories, Australia

*Louise S Conwell, Endocrinology and Diabetes, Lady Cilento Children's Hospital, Stanley St, South Brisbane, Brisbane, Queensland, 4101, Australia. Louise.Conwell@health.qld.gov.au.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 14 MAR 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Aris 2000 {published data only}
  • Aris RM, Lester GE, Neuringer IP, Winders AW, Gott KK, Rea J, et al. Efficacy of pamidronate for osteoporosis in cystic fibrosis patients following lung transplantation [abstract]. Pediatric Pulmonology 1998;Suppl 17:365.
  • Aris RM, Lester GE, Renner JB, Winders A, Denene Blackwood A, Lark RK, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. American Journal of Respiratory and Critical Care Medicine 2000;162(3 part 1):941-6.
  • Aris RM, Ontjes DA, Winders AW, Blackwood D, Lester GE. Effect of pamidronate on bone biomarkers in post-transplant osteoporotic cystic fibrosis patients [abstract]. Pediatric Pulmonology 1998;Suppl 17:364-5.
Aris 2004 {published data only}
  • Aris RM, Lester GE, Camaniti M, Hensler M, Lark RK, Hecker TM, et al. Efficacy of alendronate in CF adults with low bone density. Pediatric Pulmonology 2003;S25:351.
  • Aris RM, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, Hecker TM, Renner JB, Guillen U, Brown SA, Neuringer IP, Chalermskulrat W, Ontjes DA. Efficacy of alendronate in adults with cystic fibrosis with low bone density. American journal of respiratory and critical care medicine 2004;169(1):77-82.
Boyle 2005 {published data only}
  • Boyle MP, Lechtzin N, Watts S. Zoledronate therapy for decreased bone density in adults with cystic fibrosis [abstract]. Pediatric Pulmonology 2005;40(S28):353.
Chapman 2009 {published data only}
  • Chapman I, Greville H, Ebeling PR, King SJ, Kotsimbos T, Nugent P, et al. Intravenous zoledronate improves bone density in adults with cystic fibrosis. Clinical Endocrinology 2009; Vol. 70, issue 6:838-846.
Haworth 2001 {published data only}
  • Haworth CS, Selby PL, Adams JE, Mawer EB, Horrocks AW, Webb AK. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001;56(4):314-6.
  • Haworth CS, Selby PL, Mawer EB, Adams JE, Verma A, Phillips A, et al. Pamidronate increases axial bone density in cystic fibrosis patients [abstract]. Pediatric Pulmonology 1999;Suppl 19:295.
  • Haworth CS, Selby PL, Mawer EB, Adams JE, Webb AK. Intravenous pamidronate increases axial bone density in cystic fibrosis adults [abstract]. Thorax 1999;54(Suppl 3):A67.
  • Haworth CS, Selby PL, Webb AK, Adams JE, Freemont TJ. Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis [letter]. Lancet 1999;353(9167):1886.
  • Haworth CS, Selby PL, Webb AK, Mawer EB, Adams JE, Freemont TJ. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis [letter]. Lancet 1998;352(9142):1753-4.
Haworth 2011 {published and unpublished data}
  • Haworth CS, Sharples L, Hughes V, Elkin SL, Hodson M, Conway S, Etherington C, Elborn JS, Rendall J, Wheaton E, Kadri E, Elliott J, Hlaing T, Barker H, Compston J. Two-year multicenter, randomised, double-blind, placebo-controlled trial assessing the effect of weekly Risedronate on bone mineral density in adults with CF [abstract]. Pediatric Pulmonology 2010;45(Suppl 33):423.
  • Haworth CS, Sharples L, Hughes V, Elkin SL, Hodson ME, Conway SP, et al. Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. Journal of Cystic Fibrosis 2011;10(6):470-6. [DOI: 10.1016/j.jcf.2011.07.007]
  • Haworth CS, Sharples L, Hughes V, Elsin SL, Hodson ME, Conway SP, Etherington C, Elborn JS, Rendall J, Wheaton E, Kadri E, Elliott J, Barker HC, Compston J. Multicentre randomised double blind placebo controlled trial assessing the effect of weekly risedronate on bone mineral density in adults with cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2010;9(Suppl 1):S85.
Papaioannou 2008 {published data only}
  • Papaioannou A, Kennedy CC, Freitag A, Ioannidis G, O'Neill J, Webber C, et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest 2008;134(4):794-800.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Conway 2004 {published data only}
  • Conway SP, Oldroyd B, Morton A, Truscott JG, Peckham DG. Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax 2004;59(8):699-703.
Hardin 2005 {published data only}
  • Hardin DS, Ahn C, Prestidge C, Seilheimer DK, Ellis KJ. Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of paediatric endocrinology & metabolism: JPEM 2005;18(6):589-95.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Alicandro 2013
  • Alicandro G, Bisogno A, Battezzati A, Bianchi ML, Corti F, Colombo C. Recurrent pulmonary exacerbations are associated with low fat free mass and low bone mineral density in young adults with cystic fibrosis. Journal of Cystic Fibrosis 2013 Nov 28 [Epub ahead of print]:S1569-993. [PUBMED: 24291530]
Ambroszkiewicz 2013
  • Ambroszkiewicz J, Sands D, Gajewska J, Chelchowska M, Laskowska-Klita T. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis. Advances in Medical Sciences 2013 Nov 23 [Epub ahead of print]:1-6. [PUBMED: 24277958]
Aris 1996
Aris 1998
  • Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, Lester GE, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Annals of Internal Medicine 1998;128(3):186-93.
Aris 2005
  • Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, et al. Consensus Statement: Guide to Bone Health and Disease in Cystic Fibrosis. The Journal of Clinical Endocrinology and Metabolism 2005;90(3):1888-96.
Bianchi 2006
Black 1996
  • Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348(9041):1535-41.
Boutsen 2001
  • Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone Mineral Research 2001;16(1):104-12.
Boyle 2006
Buntain 2004
  • Buntain HM, Greer RM, Schluter PJ, Wong JC, Batch JA, Potter JM, et al. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax 2004;59(2):149-55.
Buntain 2006
  • Buntain HM, Schluter PJ, Bell SC, Greer RM, Wong JC, Batch J, et al. Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax 2006;61(2):146-54.
Caldeira 2008
  • Caldeira RJ, Fonseca VD, Gomes Junio SC, de Miranda Chaves CR. Prevalence of bone mineral disease among adolescents with cystic fibrosis. Journal of Pediatrics 2008;84(1):18-25.
Cates 2003 [Computer program]
  • Cates C. Visual Rx. Online NNT Calculator. http://www.nntonline.net/: Cates C, 2003.
Cryer 2002
Cummings 1995
  • Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. New England Journal of Medicine 1995;332(12):767-73.
Cystic Fibrosis Foundation Patient Registry 2013
  • Cystic Fibrosis Foundation. Patient Registry 2012 Annual Report. Bethesda, Maryland: Cystic Fibrosis Foundation, 2013.
Cystic Fibrosis Trust Report 2007
  • Cystic Fibrosis Trust. Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Kent: Cystic Fibrosis Trust, February 2007.
Dif 2004
Donadio 2013
  • Donadio MV, Souza GC, Tiecher G, Heinzmann-Filho JP, Paim TF, Hommerding PX, et al. Bone mineral density, pulmonary function, chronological age, and age at diagnosis in children and adolescents with cystic fibrosis. Jornal de Pediatria 2013;89(2):151-7. [PUBMED: 23642425]
Eggelmeijer 1996
  • Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis and Rheumatism 1996;39(3):396-402.
Fromm 1991
  • Fromm G, Vega E, Plantalech L, Galich AM, Mautalen CA. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis International 1991;1(3):129-33.
Giger 2013
  • Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. Journal of Controlled Release: official journal of the Controlled Release Society 2013;167(2):175-88. [PUBMED: 23395668]
Glorieux 1998
  • Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. The New England Journal of Medicine 1998;339(14):947-52.
Gore 2010
  • Gore AP, Kwon SH, Stenbit AE. A roadmap to the brittle bones of cystic fibrosis. Journal of Osteoporosis 2010;2011:926045. [PUBMED: 21209785]
Greer 2003
  • Greer RM, Buntain HM, Potter JM, Wainwright CE, Wong JC, O'Rourke PK, et al. Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls. Osteoporosis International 2003;14(5):404-11.
Hall 2010
Haworth 2010b
Hayes 2011
  • Hayes M, Yaster M, Haythornthwaite JA, Riekert K, Nelson K, White E, et al. Pain is a common problem affecting clinical outcomes in adults with cystic fibrosis. Chest 2011;140(6):1598-603. [PUBMED: 21659431]
Higgins 2003
Higgins 2011
  • Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
ISCD Official Positions 2013
  • International Society for Clinical Densitometry. 2013 ISCD Official Positions [Updated August 2013]. www.iscd.org (accessed 27 January 2014).
Jadad 1996
  • Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled clinical trials 1996;17(1):1-12.
Javier 2011
Kanis 1994
  • Kanis JA. Osteoporosis. Philadelphia: Blackwell Science, 1994.
Kelly 2013
Le Henaff 2012
  • Le Henaff C, Gimenez A, Hay E, Marty C, Marie P, Jacquot J. The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation. The American Journal of Pathology 2012;180(5):2068-75. [PUBMED: 22449949]
Le Heron 2010
  • Le Heron L, Guillaume C, Velard F, Braux J, Touqui L, Moriceau S, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. Journal of Cystic Fibrosis 2010;9(1):69-72. [PUBMED: 20005786]
Legroux-Gerot 2012
  • Legroux-Gerot I, Leroy S, Prudhomme C, Perez T, Flipo RM, Wallaert B, et al. Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers. Joint, bone, spine : revue du rhumatisme 2012;79(1):73-7. [PUBMED: 21733729]
Paccou 2010
  • Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcified Tissue International 2010;86(1):1-7. [PUBMED: 19949942]
Paccou 2013
Pendrys 2008
  • Pendrys DG, Silverman SL. Osteonecrosis of the jaws and bisphosphonates. Current osteoporosis reports 2008;6(1):31-8.
Phillipi 2008
Quon 2012
Review Manager 2003 [Computer program]
  • The Cochrane Collaboration. Review Manager (RevMan). Version 4.2 for Windows. Oxford, England: The Cochrane Collaboration, 2003.
Review Manager 2011 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Riordan 1989
Rowland 2011
Russell 2006
Russell 2007
Saag 1998
  • Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New England Journal of Medicine 1998;339(5):292-9.
Saleh 2013
Sauty 1996
  • Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996;18(2):133-9.
Sermet-Gaudelus 2007
  • Sermet-Gaudelus I, Souberbielle JC, Ruiz JC, Vrielynck S, Heullion B, Azhar I, et al. Low bone mineral density in young children with cystic fibrosis. American Journal of Respiratory & Critical Care Medicine 2007;175(9):951-7.
Sermet-Gaudelus 2011
  • Sermet-Gaudelus I, Bianchi ML, Garabedian M, Aris RM, Morton A, Hardin DS, et al. European cystic fibrosis bone mineralisation guidelines. Journal of Cystic Fibrosis 2011;10 Suppl 2:S16-23. [PUBMED: 21658635]
Shead 2010
  • Shead EF, Haworth CS, Barker H, Bilton D, Compston JE. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. Journal of Cystic Fibrosis 2010;9(2):93-8. [PUBMED: 20006563]
Shmarina 2013
  • Shmarina G, Pukhalsky A, Petrova N, Zakharova E, Avakian L, Kapranov N, et al. TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression. Journal of Translational Medicine 2013;11:19. [PUBMED: 23343370]
Stalvey 2013
  • Stalvey MS, Clines KL, Havasi V, McKibbin CR, Dunn LK, Chung WJ, et al. Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease. PloS One 2013;8(11):e80098. [PUBMED: 24236172]
Stalvey 2013a
  • Stalvey MS, Clines GA. Cystic fibrosis-related bone disease: insights into a growing problem. Current Opinion in Endocrinology, Diabetes and Obesity 2013;20(6):547-52. [PUBMED: 24468756]
Steer 1997
  • Steer JH, Vuong Q, Joyce DA. Suppression of human monocyte tumour necrosis factor-alpha release by glucocorticoid therapy: relationship to systemic monocytopaenia and cortisol suppression. British Journal of Clinical Pharmacology 1997;43(4):383-9.
Watts 1990
  • Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New England Journal of Medicine 1990;323(2):73-9.
Weitzmann 2013
  • Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica 2013;2013:125705. [PUBMED: 24278766]
Wells 2008
  • Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004523.pub3]
Yankaskas 1999
  • Yankaskas JR, Knowles MR. Cystic Fibrosis in Adults. Philadelphia: Lippincott-Raven, 1999.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Brenckmann 2001
Conwell 2009
Conwell 2012